T-cell therapy using genetically engineered T cells modified with either T cell receptor or chimeric
antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain
despite recent successes in clinical trials. Temporal and spatial control of the engineered therapeutic T cells may
improve the safety profile of these treatment regimens. To achieve these goals, numerous approaches have been
tested and utilized including the incorporation of a suicide gene, the switch-mediated activation, the combinatorial
antigen recognition, etc. This review will summarize the toxicities caused by engineered T cells and novel strategies
to overcome them.
Keywords: Immunotherapy, Genetically engineered T cells, Chimeric antigen receptor, Gene therapy, T-cell therapy, suicide gene.
open access plus
Rights & PermissionsPrintExport